CVS Health Initially excludes Gilead Sciences’ New HIV Prevention Drug
Table of Contents
CVS Health, the largest pharmacy manager in the United states, will not initially include Gilead sciences’ (GILD) new HIV prevention medication in it’s commercial plans. This decision, despite the drug’s proven effectiveness, was communicated to Reuters by a CVS spokesperson.
Reasons for the Exclusion
CVS health justified its decision by citing a combination of clinical, financial, and regulatory factors. According to spokesperson David Whitrap, the company will not cover Yeztugo (the new medication) as part of its Affordable Care Act (ACA) plans. this is because CVS’s ACA prevention program adheres to the recommendations and requirements set forth by the U.S. Department of Health and Human Services (HHS).
Current HIV Prevention Recommendations
The current HIV prevention recommendations from the U.S.Preventive Services Task Force (USPSTF), which is supported by the HHS, currently only encompass three older medications. These established medications have a long track record of use and are well-defined within existing guidelines. The USPSTF regularly updates its recommendations based on new evidence, and Yeztugo’s inclusion will likely be considered in future reviews.
Understanding the Implications
This initial exclusion means that many individuals with CVS insurance may face out-of-pocket costs for Yeztugo if they wish to utilize it for HIV prevention. This raises concerns about access to the latest advancements in preventative healthcare, particularly for those who might potentially be cost-sensitive.
What is Yeztugo?
Yeztugo (lenacapavir) is a first-in-class capsid inhibitor for HIV-1 prevention. Unlike existing preventative medications like PrEP (pre-exposure prophylaxis), which need to be taken daily, yeztugo is administered as an injection every six months. This less frequent dosing schedule offers a significant convenience factor for individuals at risk of HIV infection. Clinical trials have demonstrated Yeztugo’s high efficacy in preventing HIV acquisition.
Future Outlook
CVS Health has not ruled out covering Yeztugo in the future. The company stated it will continue to evaluate the drug as new clinical and economic data become available. It’s also possible that the USPSTF will update its recommendations to include Yeztugo, which would likely prompt CVS to reconsider its coverage policy. The situation highlights the complex interplay between pharmaceutical innovation, healthcare guidelines, and insurance coverage decisions.
Key Takeaways
- CVS Health will not initially cover Gilead Sciences’ Yeztugo in its commercial plans.
- The decision is based on clinical, financial, and regulatory factors, aligning with HHS recommendations.
- current USPSTF guidelines only recommend three older HIV prevention medications.
- Yeztugo offers a less frequent dosing schedule (every six months) compared to daily PrEP.
- CVS Health may reconsider coverage as new data emerges and guidelines evolve.